KR101990605B1 - 아미노피리미딘 키나아제 억제제 - Google Patents
아미노피리미딘 키나아제 억제제 Download PDFInfo
- Publication number
- KR101990605B1 KR101990605B1 KR1020147014718A KR20147014718A KR101990605B1 KR 101990605 B1 KR101990605 B1 KR 101990605B1 KR 1020147014718 A KR1020147014718 A KR 1020147014718A KR 20147014718 A KR20147014718 A KR 20147014718A KR 101990605 B1 KR101990605 B1 KR 101990605B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- alkyl
- group
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(*)NC(CC1)CCC1Nc1nc(C=C(C(N2)=O)SC2=O)ccn1 Chemical compound CC(*)NC(CC1)CCC1Nc1nc(C=C(C(N2)=O)SC2=O)ccn1 0.000 description 4
- UMHNOUIYZUKIKH-HCHLIXBLSA-N O=C(/C(/S1)=C/c2ccnc(NC(CC3)CCC3/C=N/S(c3c4ncccc4ccc3)(=O)=O)n2)NC1=O Chemical compound O=C(/C(/S1)=C/c2ccnc(NC(CC3)CCC3/C=N/S(c3c4ncccc4ccc3)(=O)=O)n2)NC1=O UMHNOUIYZUKIKH-HCHLIXBLSA-N 0.000 description 2
- USBWZDFREGPVFW-BMHHXMESSA-N O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3c4ncccc4ccc3)n2)NC1=O Chemical compound O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3c4ncccc4ccc3)n2)NC1=O USBWZDFREGPVFW-BMHHXMESSA-N 0.000 description 2
- WHEDIEORQRTDMV-KUXDZRIFSA-N O=C(/C(/S1)=C/c2nc(NC[C@H]3CC[C@H](CNCc4nc(-c5c[s]cc5)ccc4)CC3)ncc2)NC1=O Chemical compound O=C(/C(/S1)=C/c2nc(NC[C@H]3CC[C@H](CNCc4nc(-c5c[s]cc5)ccc4)CC3)ncc2)NC1=O WHEDIEORQRTDMV-KUXDZRIFSA-N 0.000 description 2
- WSPJRAIYQWHNJO-MIWQDLDDSA-N OP(O)(OCN(C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3cccc(-c4c[s]cc4)n3)n2)=O)C1=O)=O Chemical compound OP(O)(OCN(C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3cccc(-c4c[s]cc4)n3)n2)=O)C1=O)=O WSPJRAIYQWHNJO-MIWQDLDDSA-N 0.000 description 2
- JRXXMFWRJIHIMU-UHFFFAOYSA-N CC(C)(C)OC(NCc1cccc(-c2c[s]cc2)n1)=O Chemical compound CC(C)(C)OC(NCc1cccc(-c2c[s]cc2)n1)=O JRXXMFWRJIHIMU-UHFFFAOYSA-N 0.000 description 1
- IMXUHHVSUSNYQH-DTORHVGOSA-N CC(C)(C)OC(N[C@H](CC1)CC[C@H]1NC(N)=N)=O Chemical compound CC(C)(C)OC(N[C@H](CC1)CC[C@H]1NC(N)=N)=O IMXUHHVSUSNYQH-DTORHVGOSA-N 0.000 description 1
- JMVSJRPWSKFGOS-UHFFFAOYSA-N CC(C)COP(CCCl)(OCC(C)C)=O Chemical compound CC(C)COP(CCCl)(OCC(C)C)=O JMVSJRPWSKFGOS-UHFFFAOYSA-N 0.000 description 1
- MIKQJCYETNTOGE-NHIGPITISA-N CC(OCOC(N(Cc1cccc(-c2c[s]cc2)n1)[C@H](CC1)CC[C@@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1)=O)=O Chemical compound CC(OCOC(N(Cc1cccc(-c2c[s]cc2)n1)[C@H](CC1)CC[C@@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1)=O)=O MIKQJCYETNTOGE-NHIGPITISA-N 0.000 description 1
- SCOAOSFZKFLACY-BSNWOWQPSA-N CC(OCOC(N[C@H](CC1)CC[C@@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1)=O)=O Chemical compound CC(OCOC(N[C@H](CC1)CC[C@@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1)=O)=O SCOAOSFZKFLACY-BSNWOWQPSA-N 0.000 description 1
- GOHBDVDXWRVRMM-ARIGCXPVSA-N CCCC(CCC)C(N(Cc1cccc(-c2c[s]cc2)n1)[C@H](CC1)CC[C@@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1)=O Chemical compound CCCC(CCC)C(N(Cc1cccc(-c2c[s]cc2)n1)[C@H](CC1)CC[C@@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1)=O GOHBDVDXWRVRMM-ARIGCXPVSA-N 0.000 description 1
- TYUDNXXODGWBKX-UHFFFAOYSA-N CCc1cccc(-c2c[s]cc2)n1 Chemical compound CCc1cccc(-c2c[s]cc2)n1 TYUDNXXODGWBKX-UHFFFAOYSA-N 0.000 description 1
- HMIYTCGARBRVGY-SHTZXODSSA-N CNC(N[C@H](CC1)CC[C@@H]1NCc1cccc(-c2c[s]cc2)n1)=N Chemical compound CNC(N[C@H](CC1)CC[C@@H]1NCc1cccc(-c2c[s]cc2)n1)=N HMIYTCGARBRVGY-SHTZXODSSA-N 0.000 description 1
- YNAAPBDMCJMBAP-AUSMZJMNSA-N COCCOCCN[C@H](CC1)CC[C@@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1 Chemical compound COCCOCCN[C@H](CC1)CC[C@@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1 YNAAPBDMCJMBAP-AUSMZJMNSA-N 0.000 description 1
- ISNXHDDBZZBPAJ-VVGXGZCESA-N COc1ccncc1CN[C@H](CC1)CC[C@@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1 Chemical compound COc1ccncc1CN[C@H](CC1)CC[C@@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1 ISNXHDDBZZBPAJ-VVGXGZCESA-N 0.000 description 1
- KSMVBYPXNKCPAJ-LJGSYFOKSA-N C[C@H](CC1)CC[C@@H]1N Chemical compound C[C@H](CC1)CC[C@@H]1N KSMVBYPXNKCPAJ-LJGSYFOKSA-N 0.000 description 1
- KCXVHFZYALJKQY-XFFZJAGNSA-N NC(CC1)CCC1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1 Chemical compound NC(CC1)CCC1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1 KCXVHFZYALJKQY-XFFZJAGNSA-N 0.000 description 1
- ZCHRZYFRJVHGJQ-IZLXSQMJSA-N N[C@H](CC1)CC[C@@H]1NC(N)=N Chemical compound N[C@H](CC1)CC[C@@H]1NC(N)=N ZCHRZYFRJVHGJQ-IZLXSQMJSA-N 0.000 description 1
- KCXVHFZYALJKQY-XNMCJDAHSA-N N[C@H](CC1)CC[C@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1 Chemical compound N[C@H](CC1)CC[C@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1 KCXVHFZYALJKQY-XNMCJDAHSA-N 0.000 description 1
- RFGININSPMRLIO-OXBIJSGISA-N N[C@H](CC1)CC[C@H]1Nc1nc(/C=C(/C(N2COP(O)(O)=O)=O)\SC2=O)ccn1 Chemical compound N[C@H](CC1)CC[C@H]1Nc1nc(/C=C(/C(N2COP(O)(O)=O)=O)\SC2=O)ccn1 RFGININSPMRLIO-OXBIJSGISA-N 0.000 description 1
- QRDHBCBIPKWCAP-OBDXWJEVSA-N O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc(c(-c3c[o]cc3)ccn3)c3F)n2)NC1=O Chemical compound O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc(c(-c3c[o]cc3)ccn3)c3F)n2)NC1=O QRDHBCBIPKWCAP-OBDXWJEVSA-N 0.000 description 1
- NIGHEDAWBBMMED-TZCGUCFASA-N O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc(cccc3)c3-c3ccc[o]3)n2)NC1=O Chemical compound O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc(cccc3)c3-c3ccc[o]3)n2)NC1=O NIGHEDAWBBMMED-TZCGUCFASA-N 0.000 description 1
- IMPAUPYHNAEEJD-BLQFWBLFSA-N O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3ccc(cc(cc4)F)c4c3)n2)NC1=O Chemical compound O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3ccc(cc(cc4)F)c4c3)n2)NC1=O IMPAUPYHNAEEJD-BLQFWBLFSA-N 0.000 description 1
- QRPLCPVIMGBVLO-INSMAYOISA-N O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3ccc(cc(cc4)F)c4n3)n2)NC1=O Chemical compound O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3ccc(cc(cc4)F)c4n3)n2)NC1=O QRPLCPVIMGBVLO-INSMAYOISA-N 0.000 description 1
- ZEJVELBFAKAXQA-WDERQAHCSA-N O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3cncc4ccccc34)n2)NC1=O Chemical compound O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3cncc4ccccc34)n2)NC1=O ZEJVELBFAKAXQA-WDERQAHCSA-N 0.000 description 1
- IPPUSYOGHOEVFP-HJGBLPHTSA-N O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3cnccc3)n2)NC1=O Chemical compound O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3cnccc3)n2)NC1=O IPPUSYOGHOEVFP-HJGBLPHTSA-N 0.000 description 1
- BEOWJGPDFXWFMX-FZKJSALVSA-N O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3cnccc3Cl)n2)NC1=O Chemical compound O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3cnccc3Cl)n2)NC1=O BEOWJGPDFXWFMX-FZKJSALVSA-N 0.000 description 1
- YWNCUPKBVCIFDI-QOSOPVBXSA-N O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3cncnc3)n2)NC1=O Chemical compound O=C(/C(/S1)=C/c2ccnc(N[C@H](CC3)CC[C@@H]3NCc3cncnc3)n2)NC1=O YWNCUPKBVCIFDI-QOSOPVBXSA-N 0.000 description 1
- IIGNCHWLGQKOIP-FLIBITNWSA-N O=C(/C(/S1)=C/c2ccnc(Nc3ccccc3)n2)NC1=O Chemical compound O=C(/C(/S1)=C/c2ccnc(Nc3ccccc3)n2)NC1=O IIGNCHWLGQKOIP-FLIBITNWSA-N 0.000 description 1
- DKYISRINMRHYSL-WDERQAHCSA-N O=C(/C(/S1)=C/c2nc(N[C@H](CC3)CC[C@@H]3NCc3cnccc3-c3c[o]cc3)ncc2)NC1=O Chemical compound O=C(/C(/S1)=C/c2nc(N[C@H](CC3)CC[C@@H]3NCc3cnccc3-c3c[o]cc3)ncc2)NC1=O DKYISRINMRHYSL-WDERQAHCSA-N 0.000 description 1
- RSEGANSIHZTATB-PFKPOVMJSA-N O=C(c1cccc2cccnc12)N[C@H](CC1)CC[C@@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1 Chemical compound O=C(c1cccc2cccnc12)N[C@H](CC1)CC[C@@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1 RSEGANSIHZTATB-PFKPOVMJSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555617P | 2011-11-04 | 2011-11-04 | |
| US61/555,617 | 2011-11-04 | ||
| PCT/US2012/061597 WO2013066684A1 (en) | 2011-11-04 | 2012-10-24 | Aminopyrimidine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140098105A KR20140098105A (ko) | 2014-08-07 |
| KR101990605B1 true KR101990605B1 (ko) | 2019-06-18 |
Family
ID=47116510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147014718A Expired - Fee Related KR101990605B1 (ko) | 2011-11-04 | 2012-10-24 | 아미노피리미딘 키나아제 억제제 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8927525B2 (enExample) |
| EP (1) | EP2776432B1 (enExample) |
| JP (1) | JP6215832B2 (enExample) |
| KR (1) | KR101990605B1 (enExample) |
| CN (1) | CN104011046B (enExample) |
| AU (1) | AU2012332931B2 (enExample) |
| BR (1) | BR112014010563B1 (enExample) |
| CA (1) | CA2853454C (enExample) |
| ES (1) | ES2629690T3 (enExample) |
| IL (1) | IL232234A0 (enExample) |
| MX (1) | MX347191B (enExample) |
| PL (1) | PL2776432T3 (enExample) |
| RU (1) | RU2674017C2 (enExample) |
| WO (1) | WO2013066684A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563539B2 (en) * | 2009-12-23 | 2013-10-22 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| CA2832865C (en) * | 2011-04-22 | 2021-05-11 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| RU2674017C2 (ru) | 2011-11-04 | 2018-12-04 | ДЖАСКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Аминопиримидиновые ингибиторы киназ |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| ME03780B (me) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| DK3331877T3 (da) * | 2015-08-04 | 2022-01-03 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Pyrazolpyrimidinderivat og anvendelser deraf |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| JP7142646B2 (ja) | 2017-02-01 | 2022-09-27 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー． | がんを治療するためのｃｋ１及び／又はｉｒａｋ１インヒビターとしてのｎ１－（４－（５－（シクロプロピルメチル）－１－メチル－１ｈ－ピラゾール－４－イル）ピリジン－２－イル）シクロヘキサン－１，４－ジアミン誘導体及び関連化合物 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| BR112022006791A2 (pt) | 2019-10-09 | 2022-06-28 | Bayer Ag | Novos compostos heteroaril-triazol como pesticidas |
| WO2025132870A1 (en) * | 2023-12-21 | 2025-06-26 | Glaxosmithkline Intellectual Property (No.4) Limited | Chemical compounds and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011079274A1 (en) * | 2009-12-23 | 2011-06-30 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW245716B (enExample) | 1992-12-28 | 1995-04-21 | Takeda Pharm Industry Co | |
| US5955481A (en) | 1994-03-28 | 1999-09-21 | Nissan Chemical Industries, Ltd. | Pyridine type thiazolidines |
| TW420669B (en) * | 1994-03-28 | 2001-02-01 | Nissan Chemical Ind Ltd | Pyridine type thiazolidines |
| ATE238297T1 (de) | 1994-10-20 | 2003-05-15 | Nippon Chemiphar Co | Chinolinderivat |
| CN101006078A (zh) | 2004-06-17 | 2007-07-25 | 惠氏公司 | 促性腺素释放激素受体拮抗剂 |
| MX2007002604A (es) * | 2004-09-03 | 2007-04-25 | Applied Research Systems | Azolidinonas de piridina metileno y uso de las mismas. |
| EA200700848A1 (ru) | 2004-10-12 | 2007-10-26 | Апплайд Резеч Системз Арс Холдинг Н. В. | Ингибиторы pi3-гамма-киназы для лечения анемии |
| EP1916249A1 (en) | 2006-10-10 | 2008-04-30 | LEK Pharmaceuticals D.D. | 3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(thio)oxo-2-(thio)oxo-azolidin-5-ylidene derivatives as antibacterial agents |
| US20110263664A1 (en) * | 2007-11-15 | 2011-10-27 | Musc Foundation For Research Development | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer |
| WO2009097113A2 (en) | 2008-01-28 | 2009-08-06 | New York University | Oxazole and thiazole compounds as b-catenin modulators and uses thereof |
| BRPI0919625A2 (pt) | 2008-10-29 | 2015-12-01 | Sirtris Pharmaceutical Inc | piriridina, piridina bicíclica e análogos relacionados como moduladores de sirtuína |
| US20100331315A1 (en) * | 2009-06-18 | 2010-12-30 | Mustapha Haddach | Rhodanines and related heterocycles as kinase inhibitors |
| CA2832865C (en) | 2011-04-22 | 2021-05-11 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| RU2674017C2 (ru) | 2011-11-04 | 2018-12-04 | ДЖАСКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Аминопиримидиновые ингибиторы киназ |
-
2012
- 2012-10-24 RU RU2014122344A patent/RU2674017C2/ru active
- 2012-10-24 EP EP12780393.0A patent/EP2776432B1/en active Active
- 2012-10-24 WO PCT/US2012/061597 patent/WO2013066684A1/en not_active Ceased
- 2012-10-24 PL PL12780393T patent/PL2776432T3/pl unknown
- 2012-10-24 CA CA2853454A patent/CA2853454C/en active Active
- 2012-10-24 US US13/659,343 patent/US8927525B2/en active Active
- 2012-10-24 ES ES12780393.0T patent/ES2629690T3/es active Active
- 2012-10-24 MX MX2014005052A patent/MX347191B/es active IP Right Grant
- 2012-10-24 BR BR112014010563-4A patent/BR112014010563B1/pt not_active IP Right Cessation
- 2012-10-24 JP JP2014539984A patent/JP6215832B2/ja not_active Expired - Fee Related
- 2012-10-24 AU AU2012332931A patent/AU2012332931B2/en active Active
- 2012-10-24 CN CN201280053781.XA patent/CN104011046B/zh not_active Expired - Fee Related
- 2012-10-24 KR KR1020147014718A patent/KR101990605B1/ko not_active Expired - Fee Related
-
2014
- 2014-04-24 IL IL232234A patent/IL232234A0/en active IP Right Grant
- 2014-12-19 US US14/577,079 patent/US9629840B2/en active Active
-
2016
- 2016-12-09 US US15/374,013 patent/US10336743B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011079274A1 (en) * | 2009-12-23 | 2011-06-30 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| US20130310342A1 (en) | 2013-11-21 |
| US20150202205A1 (en) | 2015-07-23 |
| US10336743B2 (en) | 2019-07-02 |
| JP6215832B2 (ja) | 2017-10-18 |
| EP2776432B1 (en) | 2017-03-29 |
| AU2012332931A1 (en) | 2014-06-12 |
| BR112014010563A2 (pt) | 2017-04-25 |
| JP2015501782A (ja) | 2015-01-19 |
| RU2014122344A (ru) | 2015-12-10 |
| US20170247367A1 (en) | 2017-08-31 |
| PL2776432T3 (pl) | 2017-10-31 |
| KR20140098105A (ko) | 2014-08-07 |
| US8927525B2 (en) | 2015-01-06 |
| CN104011046B (zh) | 2017-05-03 |
| CA2853454C (en) | 2020-01-21 |
| MX2014005052A (es) | 2015-03-19 |
| EP2776432A1 (en) | 2014-09-17 |
| WO2013066684A1 (en) | 2013-05-10 |
| BR112014010563B1 (pt) | 2021-01-12 |
| RU2674017C2 (ru) | 2018-12-04 |
| US9629840B2 (en) | 2017-04-25 |
| AU2012332931B2 (en) | 2017-08-03 |
| MX347191B (es) | 2017-04-19 |
| CA2853454A1 (en) | 2013-05-10 |
| ES2629690T3 (es) | 2017-08-14 |
| CN104011046A (zh) | 2014-08-27 |
| IL232234A0 (en) | 2014-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101990605B1 (ko) | 아미노피리미딘 키나아제 억제제 | |
| JP5793505B2 (ja) | アミノピリミジンキナーゼ阻害薬 | |
| US8901145B2 (en) | Aminopyrimidine kinase inhibitors | |
| RU2537945C2 (ru) | Триазиновые, пиримидиновые и пиридиновые аналоги и их применение в качестве терапевтических агентов и диагностических проб | |
| RU2509081C2 (ru) | Пуриновые соединения, ингибирующие рi3к, и способы применения | |
| ES2875737T3 (es) | Derivados de 2-fenil-3H-imidazo[4,5-b]piridina útiles como inhibidores de la actividad tirosina quinasa de ROR1 de mamíferos | |
| JP2010524911A (ja) | ５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用 | |
| WO2009026346A1 (en) | Thiazolidine compounds, and methods of making and using same | |
| KR20180049056A (ko) | 삼환식 축합피리딘-2－온 유도체 및 이들의 brd4 저해제로서의 용도 | |
| WO2023154426A1 (en) | Cdk inhibitors and methods of use thereof | |
| JP6858252B2 (ja) | ラパマイシンシグナル伝達経路阻害剤のメカニズム標的、及びその治療応用 | |
| US9073903B2 (en) | Imidazole-2,4-dione inhibitors of casein kinase 1 | |
| WO2023020209A1 (zh) | 含2-芳杂环取代的脲类化合物、其制备方法和用途 | |
| RU2824127C2 (ru) | Гетероциклические иммуномодуляторы в качестве ингибитора контрольных точек иммунного ответа pdl1 | |
| TW202344251A (zh) | Ａｔｒ抑制劑和其用途 | |
| RS64681B1 (sr) | Heterociklični imunomodulatori kao inhibitor kontrolne tačke pdl1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20240613 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20240613 |